Tolerance to the diuretic effects of cannabinoids and cross-tolerance to a κ-opioid agonist in THC-treated mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 358, Issue 2, 2016, Pages 334-341

  Chopda, Girish R ^a,b   Parge, Viraj ^a,c   Thakur, Ganesh A ^a   Gatley, S John ^a   Makriyannis, Alexandros ^a   Paronis, Carol A ^a,d  

^a NORTHEASTERN UNIVERSITY   (United States)

^b Dicerna Pharmaceuticals   (United States)

^c Momenta Pharmaceuticals Inc   (United States)

^d MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 9BETA (HYDROXYMETHYL) 3 (1 ADAMANTYL)HEXAHYDROCANNABINOL; CANNABINOID; CANNABINOID 1 RECEPTOR; DRONABINOL; FUROSEMIDE; KAPPA OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG; 9-(HYDROXYMETHYL)-3-(1-ADAMANTYL)HEXAHYDROCANNABINOL; ADAMANTANE; CANNABINOL; DIURETIC AGENT; KAPPA OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DIURESIS; DIURETIC ACTIVITY; DOSE RESPONSE; DRUG CROSS TOLERANCE; DRUG EFFECT; DRUG EXPOSURE; DRUG RECEPTOR BINDING; DRUG TOLERANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; URINE VOLUME; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; CEREBELLUM; DRUG EFFECTS; METABOLISM; NOCICEPTION; PHYSIOLOGY;

ADAMANTANE; ANIMALS; CANNABINOIDS; CANNABINOL; CEREBELLUM; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; DRUG TOLERANCE; MALE; MICE; NOCICEPTION; RECEPTORS, OPIOID, KAPPA;

EID: 84978758198     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.232132     Document Type: Article

References (40)

1. Ames F (1958) A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses. J Ment Sci 104:972-999.
2. Bass CE and Martin BR (2000) Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend 60: 113-119.
3. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, and Sim-Selley LJ (1999) Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-Activated G proteins in rat brain. J Neurochem 73:2447-2459.
4. Budney AJ, Moore BA, Vandrey RG, and Hughes JR (2003) The time course and significance of cannabis withdrawal. J Abnorm Psychol 112:393-402.
5. Chopda GR, Vemuri VK, Sharma R, Thakur GA, Makriyannis A, and Paronis CA (2013) Diuretic effects of cannabinoid agonists in mice. Eur J Pharmacol 721: 64-69.
6. Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, Simmons MS, and Gorelick DA (2006) Cannabis withdrawal among non-treatmentseeking adult cannabis users. Am J Addict 15:8-14.
7. Desai RI, Thakur GA, Vemuri VK, Bajaj S, Makriyannis A, and Bergman J (2013) Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and noncannabinoid drugs. J Pharmacol Exp Ther 344:319-328.
8. Fan F, Compton DR, Ward S, Melvin L, and Martin BR (1994) Development of crosstolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. J Pharmacol Exp Ther 271:1383-1390.
9. Garzón J, de la Torre-Madrid E, Rodríguez-Muñoz M, Vicente-Sánchez A, and Sánchez-Blázquez P (2009) Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine. Mol Pain 5: 11. doi:10.1186/1744-8069-5-11
10. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, Gifford AN, Pyatt B, Dewey SL, and Makriyannis A (1998) Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem 70:417-423.
11. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, and Maldonado R (2002) Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 22:1146-1154.
12. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, and Volkow ND (1999) Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 288:478-483.
13. Hampson RE, Mu J, and Deadwyler SA (2000) Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons. J Neurophysiol 84:2356-2364.
14. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
15. Hruba L, Ginsburg BC, and McMahon LR (2012) Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by D?-tetrahydrocannabinol treatment in rhesus monkeys. J Pharmacol Exp Ther 342: 843-849.
16. Leander JD, Hart JC, and Zerbe RL (1987) Kappa agonist-induced diuresis: evidence for stereoselectivity, strain differences, independence of hydration variables and a result of decreased plasma vasopressin levels. J Pharmacol Exp Ther 242:33-39.
17. Leander JD, Zerbe RL, and Hart JC (1985) Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine. J Pharmacol Exp Ther 234:463-469.
18. Maguire DR, Yang W, and France CP (2014) Interactions between m-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-Administration. J Pharmacol Exp Ther 345:354-362.
19. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, and Ward SJ (1991) Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478.
20. McKinney DL, CassidyMP, Collier LM,Martin BR,Wiley JL, Selley DE, and Sim-Selley LJ (2008) Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 324:664-673.
21. Mendizábal V, Zimmer A, and Maldonado R (2006) Involvement of kappa/dynorphin system in WIN 55,212-2 self-Administration in mice. Neuropsychopharmacology 31:1957-1966.
22. Nguyen PT, Schmid CL, Raehal KM, Selley DE, Bohn LM, and Sim-Selley LJ (2012) b-Arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner. Biol Psychiatry 71:714-724.
23. Pacher P, Bátkai S, and Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462.
24. Parker CS and Wrigley F (1947) Effects of cannabis. Lancet 2:223.
25. Paronis CA, Nikas SP, Shukla VG, and Makriyannis A (2012) D(9)-Tetrahydrocannabinol acts as a partial agonist/antagonist in mice. Behav Pharmacol 23:802-805.
26. Paronis CA, Thakur GA, Bajaj S, Nikas SP, Vemuri VK, Makriyannis A, and Bergman J (2013) Diuretic effects of cannabinoids. J Pharmacol Exp Ther 344:8-14.
27. Paronis CA and Woods JH (1997) Clocinnamox dose-dependently antagonizes morphine-Analgesia and [3H]DAMGO binding in rats. Eur J Pharmacol 337:27-34.
28. Pugh G, Jr., Smith PB, Dombrowski DS, and Welch SP (1996) The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 279:608-616.
29. Rios C, Gomes I, and Devi LA (2006) mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148:387-395.
30. Sáez-Cassanelli JL, Fontanella GH, Delgado-García JM, and Carrión AM (2007) Functional blockage of the cannabinoid receptor type 1 evokes a kappa-opiatedependent analgesia. J Neurochem 103:2629-2639.
31. Shuster SJ, Riedl M, Li X, Vulchanova L, and Elde R (1999) Stimulus-dependent translocation of k opioid receptors to the plasmamembrane. J Neurosci 19:2658-2664.
32. Sim-Selley LJ and Martin BR (2002) Effect of chronic administration of R-(1)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 303:36-44.
33. Sim-Selley LJ, Schechter NS, Rorrer WK, Dalton GD, Hernandez J, Martin BR, and Selley DE (2006) Prolonged recovery rate of CB1 receptor adaptation after cessation of long-term cannabinoid administration. Mol Pharmacol 70:986-996.
34. Singh H, Schulze DR, and McMahon LR (2011) Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia. Psychopharmacology (Berl) 215:665-675.
35. Smith PB, Welch SP, and Martin BR (1994) Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 268: 1381-1387.
36. Sofia RD, Knobloch LC, Harakal JJ, and Erikson DJ (1977) Comparative diuretic activity of delta9-tetrahydrocannabinol, cannabidiol, cannabinol and hydrochlorothiazide in the rat. Arch Int Pharmacodyn Ther 225:77-87.
37. Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, and Fantegrossi WE (2015) Repeated administration of phytocannabinoid D(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacol Res 102: 22-32.
38. Tam J, Vemuri VK, Liu J, Bátkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, and Pickel J, et al. (2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120:2953-2966.
39. United Nations Office on Drugs and Crime (UNODC) (2014) World Drug Report, United Nations, http://www.unodc.org/wdr2014/.
40. Walentiny DM, Vann RE, Warner JA, King LS, Seltzman HH, Navarro HA, Twine CE, Jr., Thomas BF, Gilliam AF, and Gilmour BP, et al. (2010) Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents. Psychopharmacology (Berl) 210:275-284.